Crossmark

Acellular, bioresorbable, ultra-purified alginate gel implantation for intervertebral disc herniation: Phase 1/2, open-label, non-randomized clinical trials

Crossref DOI link: https://doi.org/10.1038/s41467-025-59715-0

Published Online: 2025-05-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamada, Katsuhisa https://orcid.org/0000-0002-9841-5890
Hyakumachi, Takahiko

Kokabu, Terufumi

Maeda, Kenichiro

Isoe, Toshiyuki

Tha, Khin Khin https://orcid.org/0000-0002-9072-4509
M. Ito, Yoichi

Ohnishi, Takashi https://orcid.org/0000-0002-9228-7250
Endo, Tsutomu

Ukeba, Daisuke https://orcid.org/0000-0002-8844-3476
Tachi, Hiroyuki

Abe, Yuichiro

Ishikawa, Yoko

Yokota, Nozomi

Miyakoshi, Takashi https://orcid.org/0000-0002-7952-862X
Sugita, Osamu

Sato, Norihiro

Iwasaki, Norimasa

Sudo, Hideki https://orcid.org/0000-0002-8635-4648
License Information

Text and Data Mining valid from 2025-05-08

Version of Record valid from 2025-05-08
More Information

Article History

Received: 30 September 2024

Accepted: 2 May 2025

First Online: 8 May 2025

Competing interests

: Patents pertaining to this work have been filed (inventors: H.S. and N.I.). The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below